Chiasma's Mycapssa Associated With Positive Patient-Reported Outcomes In Acromegaly Patients

Chiasma Inc CHMA has presented patient-reported outcomes (PROs) data from its MPOWERED Phase 3 trial of Mycapssa for acromegaly, a hormonal disorder in which the pituitary gland produces too much growth hormone.
Data demonstrated that study patients reported significantly improved quality of life and work productivity after transitioning from long-acting injectable somatostatin analogs (iSSAs) to Mycapssa.
The data were presented at the Annual American Association of Clinical Endocrinology Meeting.
In the MPOWERED study, 146 patients entered the 6-month run-in phase in which all patients received Mycapssa.
92 patients who were responders to Mycapssa at the end of run-in were then randomized into the 9-month randomized controlled treatment phase to receive Mycapssa or iSSAs.
Among the 92 randomized patients, results showed that several PROs, including quality of life and work productivity, were significantly improved at the end of the run-in phase (reflecting outcomes on Mycapssa) compared to their results at the baseline of run-in (reflecting outcomes on iSSAs).
The safety profile of Mycapssa in the MPOWERED trial was consistent with the known safety profile of octreotide but without adverse injection site reactions.
No new or unexpected safety signals were detected during the study.
Price Action: CHMA shares are up 0.23% at $4.29 during the premarket session on the last check Friday.